Market closedNon-fractional
Heron Therapeutics/HRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Heron Therapeutics
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Ticker
HRTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
126
Website
www.herontx.com
HRTX Metrics
BasicAdvanced
$467M
Market cap
-
P/E ratio
-$0.56
EPS
1.81
Beta
-
Dividend rate
Price and volume
Market cap
$467M
Beta
1.81
Financial strength
Current ratio
2.466
Quick ratio
1.815
Long term debt to equity
-521.335
Total debt to equity
-530.625
Interest coverage (TTM)
-16.74%
Management effectiveness
Return on assets (TTM)
-18.45%
Return on equity (TTM)
358.23%
Valuation
Price to revenue (TTM)
3.429
Price to book
-13.77
Price to tangible book (TTM)
-13.77
Price to free cash flow (TTM)
-10.128
Growth
Revenue change (TTM)
16.05%
Earnings per share change (TTM)
-58.24%
3-year revenue growth (CAGR)
16.63%
3-year earnings per share growth (CAGR)
-39.45%
What the Analysts think about HRTX
Analyst Ratings
Majority rating from 4 analysts.
HRTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$35M
1.17%
Net income
-$3.1M
-71.03%
Profit margin
-8.95%
-71.39%
HRTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.17
-$0.07
-$0.02
-
Expected
-$0.23
-$0.29
-$0.16
-$0.09
-$0.04
Surprise
49.96%
-41.88%
-57.23%
-77.78%
-
HRTX News
AllArticlesVideos
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
PRNewsWire·2 weeks ago
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PRNewsWire·4 weeks ago
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Heron Therapeutics stock?
Heron Therapeutics (HRTX) has a market cap of $467M as of July 27, 2024.
What is the P/E ratio for Heron Therapeutics stock?
The price to earnings (P/E) ratio for Heron Therapeutics (HRTX) stock is 0 as of July 27, 2024.
Does Heron Therapeutics stock pay dividends?
No, Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Heron Therapeutics dividend payment date?
Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Heron Therapeutics?
Heron Therapeutics (HRTX) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Heron Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.